385 References 457. Vernet C, Arnulf I. Narcolepsy with long sleep time: a specific entity? Sleep. 2009;32(9):1229-35. 458. Evangelista E, Rassu AL, Lopez R, Biagioli N, Chenini S, Barateau L, et al. Sleep inertia measurement with the psychomotor vigilance task in idiopathic hypersomnia. Sleep. 2022;45(1). 459. Ingravallo F, Bassi C, Zenesini C, Vignatelli L, Pagotto U, Pizza F, Plazzi G. Sex disparities in clinical features and burden of narcolepsy type 1. J Sleep Res. 2024:e14157. 460. Piilgaard L, Rose L, Gylling Hviid C, Kohlmeier KA, Kornum BR. Sex-related differences within sleep-wake dynamics, cataplexy, and EEG fast-delta power in a narcolepsy mouse model. Sleep. 2022;45(7). 461. Arthaud S, Villalba M, Blondet C, Morel AL, Peyron C. Effects of sex and estrous cycle on sleep and cataplexy in narcoleptic mice. Sleep. 2022;45(7). 462. Sun Y, Tisdale R, Park S, Ma SC, Heu J, Haire M, et al. The development of sleep/ wake disruption and cataplexy as hypocretin/orexin neurons degenerate in male vs. female Orexin/tTA; TetO-DTA Mice. Sleep. 2022;45(12). 463. Schmidt MH, Bassetti CLA. Gender differences in narcolepsy: What are recent findings telling us? Sleep. 2022;45(12). 464. Baumann CR, Stocker R, Imhof HG, Trentz O, Hersberger M, Mignot E, Bassetti CL. Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology. 2005;65(1):147-9. 465. Nozaki H, Shimohata T, Kanbayashi T, Sagawa Y, Katada S, Satoh M, et al. A patient with anti-aquaporin 4 antibody who presented with recurrent hypersomnia, reduced orexin (hypocretin) level, and symmetrical hypothalamic lesions. Sleep Med. 2009;10(2):253-5. 466. Kanbayashi T, Arii J, Kubota H, Yano T, Kashiwagi M, Yoshikawa S, et al. [Symptomatic hypersomnia due to orexin deficiency in hypothalamic lesions]. No To Hattatsu. 2006;38(5):340-5. 467. Bernstein DL, Badve PS, Barson JR, Bass CE, Espana RA. Hypocretin receptor 1 knockdown in the ventral tegmental area attenuates mesolimbic dopamine signaling and reduces motivation for cocaine. Addict Biol. 2018;23(5):1032-45. 468. Monkemeyer N, Thomas SV, Hilleman DE, Malesker MA. Insomnia Treatment Update With a Focus on Orexin Receptor Antagonists. Us Pharm. 2022;47(5):43-8. 469. Illenberger JM, Flores-Ramirez FJ, Matzeu A, Mason BJ, Martin-Fardon R. Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats. Front Pharmacol. 2023;14:1127735. 470. Fulong X, Spruyt K, Xiaosong D, Zhaolong C, Jun Z, Fang H. Morphological and Age-Related Changes in the Narcolepsy Brain. Cereb Cortex. 2021;31(12):5460-9. 471. Hovi M, Roine U, Autti T, Heiskala H, Roine T, Kirjavainen T. Microstructural White Matter Abnormalities in Children and Adolescents With Narcolepsy Type 1. Pediatr Neurol. 2024;153:56-64. 472. Ballotta D, Talami F, Pizza F, Vaudano AE, Benuzzi F, Plazzi G, Meletti S. Hypothalamus and amygdala functional connectivity at rest in narcolepsy type 1. Neuroimage Clin. 2021;31:102748. 473. Xiao F, Lu C, Zhao D, Zou Q, Xu L, Li J, et al. Independent Component Analysis and Graph Theoretical Analysis in Patients with Narcolepsy. Neurosci Bull. 2019;35(4):743-55. 12
RkJQdWJsaXNoZXIy MjY0ODMw